Please login to the form below

Not currently logged in

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients


Roche is hoping to quickly extend the use of its breast cancer drug Kadcyla, after it submitted an application to the FDA under its new 'Real Time' review process.

The Real-Time Oncology review, which the FDA began piloting last year, allows the regulator to access clinical data immediately after 'data lock' on a trial, and before a company carries out its own analysis - helping to direct the company as to what data would help clinch an approval.

Roche is taking advantage of this process with Kadcyla, which was first cleared as a therapy for patients with HER2-positive, late-stage metastatic breast cancer who have previously been treated with Herceptin and taxane-based chemotherapy back in 2013.

It is now hoping to build on that approval as an adjuvant treatment for those with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

"Kadcyla was granted Breakthrough Therapy Designation and is also the first Roche medicine to be reviewed under the FDA's Real-Time Oncology Review pilot programme" said Sandra Horning, Roche's chief medical officer and head of global product development.

"We are working closely with the FDA to bring Kadcyla to people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy as early as possible," she adds.

The application is based on the results of the phase 3 KATHERINE study, which showed that as a second-line treatment, Kadcyla significantly reduced invasive disease-free survival compared to its breast cancer blockbuster Herceptin.

Herceptin and follow-up Perjeta are already approved for neoadjuvant use in this indication, but it doesn’t always clear away all tumour tissue, which could dramatically increase the risk of the cancer returning.


After three years of treatment, just over 88% of those treated with Kadcyla did not see their breast cancer return, compared to 77% of those treated with Herceptin.

The antibody-drug conjugate is engineered to deliver potent chemotherapy directly into HER2-positive cancer cells, potentially limiting damage to health tissues.

It combines two anti-cancer properties, trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1, which it licensed from biotech ImmunoGen.

Expanding Kadcyla's use will help Roche offset Herceptin biosimilars in the US, where the Herceptin patent is due to expire in June 2019.

It is already feeling the pressure in the EU, where recent Q4 results saw a decline in sales due to the approval of several Herceptin biosimilars.

Article by
Gemma Jones

5th February 2019

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...